Clinical trials: Inhibition, Psychological
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM)…
- Trial name
- NCT02833844
- Testing
- Evolocumab
- Where
- 78 sites in United States, Australia and 13 more
- Volunteers
- 467 people
- Sponsor
- Amgen
Impulsive Behavior, Mental Disorders
Cognitive Control Training for Urgency in a Naturalistic Clinical Setting
This study is designed to test whether computer-based cognitive exercises are helpful for reducing a specific type of impulsivity.
- Trial name
- NCT03527550
- Testing
- Cognitive Control Training
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Mclean Hospital
Multiple Sclerosis
Neuroproprioceptive "Facilitation, Inhibition" and Brain Plasticity
This study investigates whether neuroproprioceptive "facilitation, inhibition" physical therapy induces plastic and adaptive processes of the CNS (white matter integrity changes), if they relate to clinical improvement, and…
- Trial name
- NEFAI (NCT04355663)
- Testing
- Motor program activating therapy, Vojta's reflex locomotion, Functional electric stimulation
- Volunteers
- 92 people
- Sponsor
- Charles University, Czech Republic
Granuloma Annulare
Janus Kinase Inhibition in Granuloma Annulare
The primary objective is to determine if JAK1 specific inhibition is effective in treating granuloma annulare (GA), a problematic inflammatory skin disease without an FDA approved treatment.
- Trial name
- NCT05650736
- Testing
- Abrocitinib 200 mg
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- William Damsky
Subjects With Hyperlipidemia, Dyslipidemia
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
- Trial name
- ANITSCHKOW (NCT02729025)
- Testing
- Evolocumab
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity.
- Trial name
- NCT02253394
- Testing
- Ambrisentan plus Spironolactone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Atherosclerotic Cardiovascular Disease
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the risk of coronary death, myocardial infarction…
- Trial name
- REVEAL (NCT01252953)
- Testing
- Anacetrapib
- Where
- United Kingdom
- Volunteers
- 30,449 people
- Sponsor
- University of Oxford
Peripheral Nerve Sheath Tumor
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
- Trial name
- NCT04917042
- Testing
- Tazemetostat
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Florida